1134-08-3

Upstream product

• 112641-63-1 2-chloro-3,5-dimethoxy-benzaldehyde 
• 7311-34-4 3,5-dimethoxybenzaldehdye 
• 99-10-5 3,5-Dihydroxybenzoic acid 
• 68701-21-3 methyl 2-amino-3,5-dimethoxybenzoate 
• 76746-30-0 2-Nitro-3,5-dimethoxybenzoate de methyle 
• 1132-21-4 3,5-dimethoxybenzoic acid 
• 113884-71-2 Acide 2-nitro-3,5-dimethoxybenzoique 
• 51903-93-6 methyl 2-chloro-3,5-dimethoxybenzoate 

Relevant academic research and scientific papers

TERTIARY AMIDES AND METHOD OF USE

Compunds of Formula (I) and pharmaceutically acceptable salts thereof, wherein G1, G2, G3, L1, L2, and L3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by the modulation of lysophosphatidic acid receptor 1. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation

This invention provides bicyclic heterocycles that are useful for treating cell proliferative disorders, such as cancer and restenosis, as well as angiogenesis and atherosclerosis. We have now discovered a group of bicyclic compounds that are potent inhibitors of cyclin-dependent kinases (cdks), growth factor-mediated kinases, and non-receptor kinases. The compounds are readily synthesized and can be administered by a variety of routes, including orally, and have sufficient bioavailability for clinical use. This invention provides compounds of Formula I: where Z is N or CH; G is N or CH; W is NH, S, SO, or SO2, R1 includes phenyl and substituted phenyl, R2 includes alkyl and cycloalkyl, R3 includes alkyl and hydrogen, R8 and R9 include hydrogen and alkyl, and the pharmaceutically acceptable salts thereof. This invention also provides pharmaceutical formulations comprising a compound of Formula I together with a pharmaceutically acceptable carrier, diluent, or excipient therefor.